In 2023, Werewolf Therapeutics, Inc. anticipated multiple catalysts as the company progress the company's two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in fourth quarter of 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.89 USD | -7.67% | -5.86% | -25.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.13% | 126M | |
+34.01% | 51.07B | |
+33.84% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- HOWL Stock
- News Werewolf Therapeutics, Inc.
- Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330